Lates News

In the Chinese market, sales of Novo Nordisk's semaglutide, a diabetes drug, also fell by around 11% in the first half of this year. During the investor conference call after the financial report was released, Maziar Mike Doustdar, the current Vice President of International Business at Novo Nordisk and soon-to-be CEO after taking over from Zhou Fude on August 7th, responded to investors' concerns about the competitive challenges facing semaglutide in the Chinese market. Doustdar stated that while sales of GLP-1 diabetes drugs in China have declined, sales of weight loss drugs are gradually increasing. He explained that the decline in diabetes drug sales was due to changes in distributor inventories; and that the semaglutide weight loss drug, which was only approved last year, is currently in the ramp-up stage and has not yet penetrated further into second, third, and fourth-tier cities. (Yicai)